Contineum Therapeutics (CTNM) Competitors $10.99 +0.41 (+3.88%) Closing price 04:00 PM EasternExtended Trading$10.94 -0.05 (-0.45%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. GPCR, STOK, CRMD, NUVB, SYRE, ATAI, MLYS, PRAX, CRON, and ORICShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Structure Therapeutics (GPCR), Stoke Therapeutics (STOK), CorMedix (CRMD), Nuvation Bio (NUVB), Spyre Therapeutics (SYRE), atai Life Sciences (ATAI), Mineralys Therapeutics (MLYS), Praxis Precision Medicines (PRAX), Cronos Group (CRON), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Structure Therapeutics Stoke Therapeutics CorMedix Nuvation Bio Spyre Therapeutics atai Life Sciences Mineralys Therapeutics Praxis Precision Medicines Cronos Group Oric Pharmaceuticals Contineum Therapeutics (NASDAQ:CTNM) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Which has preferable valuation & earnings, CTNM or GPCR? Contineum Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M6.16-$42.26M-$2.20-5.00Structure TherapeuticsN/AN/A-$122.53M-$1.05-18.82 Which has more risk & volatility, CTNM or GPCR? Contineum Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.88, indicating that its share price is 288% less volatile than the S&P 500. Do analysts prefer CTNM or GPCR? Contineum Therapeutics presently has a consensus target price of $22.75, suggesting a potential upside of 107.01%. Structure Therapeutics has a consensus target price of $75.71, suggesting a potential upside of 283.17%. Given Structure Therapeutics' higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Contineum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CTNM or GPCR more profitable? Structure Therapeutics' return on equity of -21.31% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -29.75% -28.08% Structure Therapeutics N/A -21.31%-20.34% Do institutionals and insiders have more ownership in CTNM or GPCR? 91.8% of Structure Therapeutics shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer CTNM or GPCR? In the previous week, Structure Therapeutics had 8 more articles in the media than Contineum Therapeutics. MarketBeat recorded 11 mentions for Structure Therapeutics and 3 mentions for Contineum Therapeutics. Structure Therapeutics' average media sentiment score of 1.35 beat Contineum Therapeutics' score of 0.52 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStructure Therapeutics beats Contineum Therapeutics on 8 of the 15 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$296.68M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-5.0020.8978.4326.42Price / Sales6.16458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book1.439.9310.916.06Net Income-$42.26M-$53.38M$3.29B$266.28M7 Day Performance9.35%0.05%0.01%-0.76%1 Month Performance89.48%7.08%7.06%3.83%1 Year Performance-37.80%11.92%50.09%24.39% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.6831 of 5 stars$10.99+3.9%$22.75+107.0%-38.4%$296.68M$50M-5.0031Short Interest ↑GPCRStructure Therapeutics2.562 of 5 stars$18.50-0.4%$75.71+309.3%-48.4%$1.07BN/A-17.65136Positive NewsSTOKStoke Therapeutics4.5418 of 5 stars$19.24+2.0%$25.57+32.9%+31.5%$1.05B$36.56M22.56100News CoverageInsider TradeCRMDCorMedix3.5444 of 5 stars$13.90+1.2%$17.33+24.7%+134.6%$1.04B$43.47M18.5130Positive NewsShort Interest ↑NUVBNuvation Bio2.5228 of 5 stars$2.97+3.0%$7.33+147.3%+5.9%$1.01B$14.36M-4.7160News CoverageSYRESpyre Therapeutics2.7898 of 5 stars$16.70+0.7%$53.40+219.8%-36.8%$1.01BN/A-4.9273Insider TradeATAIatai Life Sciences3.5178 of 5 stars$4.64-2.2%$11.25+142.7%+270.5%$991.32M$310K-6.7080Gap UpMLYSMineralys Therapeutics1.8405 of 5 stars$14.78+0.2%$32.25+118.3%+144.8%$980.43MN/A-4.1528News CoverageAnalyst ForecastPRAXPraxis Precision Medicines2.9425 of 5 stars$46.63-0.7%$85.88+84.1%-15.9%$977.48M$7.77M-3.78110News CoverageAnalyst ForecastCRONCronos Group1.656 of 5 stars$2.54-2.1%N/A+12.9%$971.01M$117.61M50.70450ORICOric Pharmaceuticals4.7087 of 5 stars$9.67+0.6%$17.63+82.2%+5.3%$941.12MN/A-5.1380News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies GPCR Competitors STOK Competitors CRMD Competitors NUVB Competitors SYRE Competitors ATAI Competitors MLYS Competitors PRAX Competitors CRON Competitors ORIC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts